Cancer News
OncoLink Cancer News - HealthDay


J&J Halts Sales of Device Used in Uterine Fibroid Surgery

Wednesday, April 30, 2014 (Last Updated: 05/01/2014)

WEDNESDAY, April 30, 2014 (HealthDay News) -- Morcellator sales have been halted due to concerns that use of the device in fibroid removal may worsen undetected uterine sarcoma, Johnson & Johnson said Tuesday.

The company noted that while worldwide sales, distribution, and promotion of the device have been suspended, it will not be taken off the market, the Wall Street Journal reported.

J&J took the action after the U.S. Food and Drug Administration warned doctors on April 17 that using a morcellator to remove uterine fibroids risked worsening uterine sarcoma. The FDA said that one in 350 women who undergo uterine fibroid removal procedures have undetected uterine sarcoma, WSJ reported.

An FDA advisory committee will meet this summer to more closely examine morcellator use during uterine fibroid surgery. In a letter to customers, J&J said it was awaiting input from the FDA and the medical community.

Health Highlights: April 30, 2014

Specialties Hematology & Oncology
Nursing
Pharmacy
Family Practice
Geriatrics
Internal Medicine

Copyright © 2014 HealthDay. All rights reserved.


I Wish You Knew

Pain management in cancer care - are patients getting what they need?

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More